Project Oncology®: Recent Episodes
ReachMD
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
Host: Steve Jackson, PharmD
Guest: Jahan Aghalar, MD
Guest: Ulka Vaishampayan, MD
With more treatment options than ever for metastatic castration-sensitive prostate cancer (mCSPC), applying clinical trial data in everyday practice has become increasingly complex. Understanding how differences in trial design, patient populations, and clinical endpoints influence treatment decisions is essential for delivering personalized care. Join Dr. Steve Jackson as he speaks with Drs. Jahan Aghalar and Ulka Vaishampayan about practical approaches to interpreting the evidence and tailoring therapy to the patients in front of you. Dr. Aghalar is an Adjunct Assistant Professor at NYU Grossman Long Island School of Medicine, and Dr. Viashampayan is a Professor of Internal Medicine at the University of Michigan Medical School in Ann Arbor, the Director of the Phase One Program, and co-founder of the Translational and Clinical Research Program at the Rogel Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Bilal Siddiqui, MD
Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consideration of tolerability, drug interactions, and treatment access. Balancing these factors can help clinicians personalize care while supporting adherence and quality of life over time. Joining Dr. Charles Turck to share practical strategies for navigating these decisions and tailoring treatment to each patient's unique needs is Dr. Bilal Siddiqui. He's an Assistant Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.
Host: Alexandria May, PharmD, BCPS
Guest: Neil M. Iyengar, MD
As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program at Winship Cancer Institute at Emory University.
Guest: Urs Weber, MD
Advances in targeted therapies have dramatically improved outcomes for patients with ALK-positive non-small cell lung cancer, but new resistance challenges continue to emerge. In this episode, Dr. Urs Weber discusses how cancers adapt to treatment, why off-target resistance and histologic transformation are becoming increasingly important, and where future research may help close critical gaps in care. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.
Guest: Urs Weber, MD
As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.
Guest: Urs Weber, MD
For patients with ALK-positive non-small cell lung cancer, staying on therapy often means staying ahead of treatment-related toxicities. Join Dr. Urs Weber, Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus, as he explores practical strategies for toxicity management, dose optimization, and shared decision-making to help support durable outcomes.
Host: Steve Jackson, PharmD
Guest: Nisha Joseph, MD
This is a non-certified educational series produced and controlled by ReachMD.
As BCMA-directed therapies move into earlier lines of care, more patients with relapsed and refractory (R/R) multiple myeloma are entering a treatment space with limited consensus on optimal sequencing strategies. In this conversation with Dr. Steve Jackson, Dr. Nisha Joseph explores how disease biology, immune exhaustion, prior treatment response, and patient-specific factors can guide therapy selection in this population. She's an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta.
Host: Jacob Sands, MD
Guest: Jia Luo, MD
NUT carcinoma is a rare, aggressive form of cancer that’s highly resistant to therapy and has no defined standard treatment. Joining Dr. Jacob Sands to discuss the best diagnostic and treatment strategies for NUT carcinoma is Dr. Jia Luo, medical oncologist at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School in Boston.
Guest: Emily MacDuffie, MD
A recent survey conducted by physicians at Penn Medicine found that one-third of female oncologists reported experiencing infertility. Join Dr. Emily Macduffie, Radiation Oncology Resident Physician at Penn Medicine, as she speaks about potential solutions related to infertility for women in medicine based on her 2023 ASCO presentation.
Guest: Alison Wakoff Loren, MD, MSCE
Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman School of Medicine.
Host: Jacob Sands, MD
Guest: Joseph O. Jacobson, MD
Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.
Host: Jacob Sands, MD
Guest: Aliyah Pabani, MD
Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Richard T. Penson, MD, MRCP
Uterine cancer is the most common type of gynecologic malignancy in the United States, and disease mortality is on the rise. What do we need to know from recent studies to diagnose patients earlier? Take a deep dive with Dr. Charles Turck as he is joined by Dr. Richard Penson, Medical Oncologist specializing in Gynecologic Oncology at Massachusetts General Hospital in Boston.
A 2025 study in Chest evaluated PREDICT, a precision medicine program at a large academic-community practice, designed to streamline testing and expand access to personalized treatment for non-small cell lung cancer (NSCLC). Hear from ReachMD's Ryan Quigley as he shares the key impacts of this approach and implications for care delivery.
Guest: Alexis Leonard
With two FDA-approved gene therapies, including the first CRISPR-based treatment, curative strategies for sickle cell disease are continuing to expand the treatment landscape. However, challenges remain in optimizing safety and accessibility, particularly for patients unable to tolerate current myeloablative conditioning. Learn about advancements in ex vivo editing, such as improved stem cell targeting and multiplex editing, and the possibility of in vivo approaches that may help transform sickle cell disease management with Dr. Alexis Leonard, who works in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee.
Guest: Alexis Leonard
Sickle cell disease management traditionally involves two primary treatment approaches: disease-modifying therapies and curative strategies. While disease-modifying therapies can help reduce complications associated with the disease, they do not correct or fix them, which is why curative strategies are appealing to some patients and physicians. Join Dr. Alexis Leonard as she discusses the current management landscape for sickle cell disease, including disease-modifying treatments, curative strategies, and potential gene therapies. Dr. Leonard works in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee.
Guest: Alexis Leonard
CRISPR technology, while relatively new, has shown potential in treating patients with sickle cell disease by increasing fetal hemoglobin. Though this gene therapy comes with safety considerations, refinements and advancements in CRISPR technology can offer new management options for sickle cell disease patients. Learn about the history of CRISPR as a sickle cell disease treatment and the future of this strategy with Dr. Alexis Leonard, who works in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee.
Guest: David Jacobsohn
Gene therapy is redefining the treatment landscape for sickle cell disease, with approaches like gene addition, gene editing, and fetal hemoglobin induction showing promise in reducing or even eliminating symptoms. However, while these therapies offer some advantages over allogeneic stem cell transplant, they also come with significant challenges. In a conversation with Ryan Quigley, Dr. David Jacobsohn discusses considerations for these therapeutic approaches and their potential impacts on care plans for sickle cell disease patients. Dr. Jacobsohn is the Division Chief of the Blood and Marrow Transplantation Program at Children’s National Hospital and Full Professor of Pediatrics at the George Washington University in Washington, DC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathon B. Cohen, MD, MS
As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathon B. Cohen, MD, MS
As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.
Host: Ashley Baker, MSN, PMHNP
Guest: Alyssa Schlenz
Guest: Shannon Phillps
Families of children with sickle cell disease have noted both an abundance of support and significant obstacles when accessing care, ranging from knowledgeable providers and flexible scheduling to transportation concerns and insurance holdups. Joining Ashley Baker to discuss their recent research on these key facilitators and barriers are Drs. Alyssa Schlenz and Shannon Phillips. Dr. Schlenz is an Associate Professor of Pediatrics at the University of Colorado School of Medicine, and Dr. Phillips is an Associate Professor in the College of Nursing at the Medical University of South Carolina.
Host: Hallie Blevins, PhD.
Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.
Host: Ryan Quigley
In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
Host: Marlene Mimi Maeusli, PhD.
A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.
Guest: Paola Marignani, PhD, EMBA
While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.
Guest: Paola Marignani, PhD, EMBA
Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.
Host: Ryan Quigley
The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.
Guest: John Cho, MD, PhD, FRCPC
Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Samuel Yamshon, MD
The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategies in combination with chemoimmunotherapy—they raise important questions around sequencing, durability, and patient selection. Joining Dr. Charles Turck to explore the real-world implications of this evolving approach is Dr. Samuel Yamshon, Director of the Cellular Therapy Service and an Assistant Professor of Medicine at Weill Cornell Medicine in New York.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sairah Ahmed, MD
CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall response rate and sustained 24-month progression-free survival in relapsed/refractory marginal zone lymphoma. Here with Dr. Charles Turck to share the key efficacy and safety findings is Dr. Sairah Ahmed, Professor in the Department of Lymphoma and Myeloma and CAR T Program Director at MD Anderson Cancer Center.
Guest: John Cho, MD, PhD, FRCPC
While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Host: Jennifer Caudle, DO
Guest: Patrick McGill, MD
Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cancers undetected until later stages. But multi-cancer early detection (MCED) testing is reshaping the landscape with blood-based analyses of cell-free DNA and methylation patterns to identify potential cancers earlier than traditional imaging. Designed for the general population over age 50, MCED testing complements rather than replaces standard screenings, helping detect cancers at stages when treatment is most effective. Joining Dr. Jennifer Caudle to share practical strategies for integrating MCED into clinical workflows, addressing misconceptions, and streamlining follow-up protocols is Dr. Patrick McGill, board-certified family physician and Executive Vice President, Chief Transformation Officer at Community Health Network in Indianapolis.
Host: Brian P. McDonough, MD, FAAFP
Guest: Marie Wood, MD
Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate scientific rigor and clinical utility. Still, challenges remain, including false positives and integration with standard screening protocols. Joining Dr. Brian McDonough to explore the rationale for using a multi-biomarker approach to MCED testing is Dr. Marie Wood, Professor of Medicine at the University of Colorado School of Medicine and Medical Director of the Hereditary Cancer Program at the CU Cancer Center.
Host: Brian P. McDonough, MD, FAAFP
Guest: Mylynda Massart, MD, PhD
Given its ability to identify universal cancer signals across multiple tumor types, multi-cancer early detection (MCED) testing is emerging as a promising tool to complement traditional, single-cancer screening methods. Joining Dr. Brian McDonough to share practical strategies for introducing MCED testing into clinical workflows and enhancing patient engagement is Dr. Mylynda Massart. Not only is she an Associate Professor at the University of Pittsburgh School of Medicine, but she's also the Founder and Medical Director of the Primary Care Precision Medicine Clinic and Associate Director of Clinical Services for the Institute for Precision Medicine at the University of Pittsburgh Medical Center.
Host: Ryan Quigley
Guest: Hallie Blevins, PhD.
Guest: Marlene Mimi Maeusli, PhD.
With one in three eligible Americans still unscreened for colorectal cancer (CRC), there’s an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection.
Reference:
Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.
Host: Matt Birnholz, MD
Guest: Jim Foote, MBA
Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to guide individualized treatment. Dr. Matt Birnholz sits down with Jim Foote, CEO of First Ascent Biomedical, to explore how this approach delivers clinically actionable insights for relapsed and resistant cancer and empowers oncologists with faster, more targeted decision making.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sairah Ahmed, MD
The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hope S. Rugo, MD, FASCO
Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it’s also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it’s important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Guest: Komal Jhaveri, MD, FACP
The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there’s a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.
Guest: Brian Slomovitz, MD
Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.
Guest: Abiodun Ologunowa
Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in care, and the implications of evolving treatment guidelines for this population is Dr. Abiodun Ologunowa. Dr. Ologunowa is a doctoral candidate and research assistant in the Department of Pharmacy Practice and Clinical Research at the University of Rhode Island College of Pharmacy.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Manali Kamdar, MD
Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events. So to help improve patient access, a recent study explored exactly when toxicities occur and whether post-infusion monitoring could be shortened without compromising safety. And based on the findings, it’s time to rethink the 4-week monitoring window. To learn more about the study’s results and what they mean for patient monitoring, safety, and broader outcomes, tune in to hear Dr. Charles Turck speak with Dr. Manali Kamdar, who authored a poster on this topic that was presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Guest: Yogindra Persuad
Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyurea. Tune in to hear Dr. Yogindra Persuad, a physician in the Department of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, discuss a multimodal approach to care, emphasizing research on oral agents and broader symptom management beyond pain.
Guest: Parul Rai
Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screening in this population. Join Dr. Parul Rai, a physician in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee, to learn about current research, early detection strategies, and the need for more sensitive diagnostic markers to prevent severe cardiac outcomes in patients with sickle cell disease.
Guest: Nidhi Bhatt
Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-advocacy skills, and support from transition care coordinators. Tune in to hear Dr. Nidhi Bhatt, who works in the Department of Hematology at St. Jude Children’s Hospital in Memphis, Tennessee, discuss how involving patients and families early on helps identify barriers and improve long-term outcomes.
Guest: Parul Rai
Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. However, considerations remain, including their impact on cardiac health. Learn about these long-standing therapies and best practices for using them to manage sickle cell disease with Dr. Parul Rai. Dr. Rai is a physician in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee.
Guest: Yogindra Persuad
For decades, hydroxyurea has been the cornerstone therapy for sickle cell disease, but new disease-modifying therapies, curative strategies, and gene therapies are expanding options for patients. While these advancing approaches come with some risks, they can help offer symptom relief, reduce complications, and give patients more choices when it comes to managing their sickle cell disease. Hear Dr. Yogindra Persuad, a physician in the Department of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, walk through the history of sickle cell disease treatment and discuss the benefits and risks of these developing therapies.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Matthew Lunning, DO, FACP
Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.
Guest: Jorge Nieva, MD
As cancer treatment continues to evolve, at-home subcutaneous immunotherapy is at the forefront of decentralized care and research. Here to share his insights on how this delivery model could impact clinical trials and cancer care is Dr. Jorge Nieva, Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.
Guest: Jorge Nieva, MD
Despite the promising benefits for cancer patients, the at-home administration of subcutaneous immunotherapy poses complex operational and logistical challenges, like cost, payer preferences, and patient safety. Tune in to hear Dr. Jorge Nieva discuss these key factors and considerations impacting the implementation of at-home subcutaneous cancer immunotherapy delivery. Dr. Nieva is an Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.
Guest: Jorge Nieva, MD
As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the at-home administration of subcutaneous formulations of immunotherapy agents like atezolizumab could help transform the way we care for patients with cancer. Learn more with Dr. Jorge Nieva, Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.
Guest: Jorge Nieva, MD
Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for home-based subcutaneous cancer therapies is Dr. Jorge Nivea. He’s an Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.
This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.
Guest: Fernando López-Ríos, MD, PhD
Guest: Christian Rolfo, MD, PhD
Guest: Charlie Gourley, MD, PhD
In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers.
Topics of conversation include the following:
- An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results
- Targeting HER2 in lung cancer: where does IHC testing fit in?
- Ovarian cancer: challenges and considerations for HER2 IHC testing
Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer.
The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Host: Jennifer Caudle, DO
Guest: Naval Daver, MD
Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it’s also associated with more proliferative disease that’s resistant to standard therapies. Given its prevalence and potential implications, a number of different CD123-targeting approaches are under investigation, including antibody-drug conjugates, bi-specific antibodies, fusion protein, and CAR T-cell therapy. In light of these new approaches, Dr. Jennifer Caudle and Dr. Naval Daver discuss the importance of targeting CD123 in AML. Dr. Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center in Houston.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Matthew Hadfield, MD
Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.
Host: Elizabeth R. Plimack, MD, MS, FASCO
Guest: Shilpa Gupta, MD
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.
Host: Elizabeth R. Plimack, MD, MS, FASCO
Guest: Lillibeth Velasco, MSN, RN
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Host: Elizabeth R. Plimack, MD, MS, FASCO
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Host: Elizabeth R. Plimack, MD, MS, FASCO
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Guest: Efrat Dotan, MD
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.
This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups.
Complete both modules, answer pre- and post-test questions and start earning CME credits.
This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment
Guest: Efrat Dotan, MD
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.
This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups.
Complete both modules, answer pre- and post-test questions and start earning CME credits.
This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment
Guest: Michele Lambert, MD, MSTR
New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targeting drugs aim to address the root causes of ITP and offer more personalized care for patients. Dr. Lambert, the Medical Director of the Special Coagulation Laboratory and a physician in the Division of Hematology at Children’s Hospital of Philadelphia, presented on this topic at the 2024 American Society of Hematology Annual Meeting.
Guest: Cheryl Maier MD, PhD
Heparin resistance occurs when patients don’t respond to anticoagulation as expected, even with what seems like the appropriate dose. Join Dr. Cheryl Maier, who spoke about this topic at the 2024 American Society of Hematology Annual Meeting, to learn more about testing methods, the role of antithrombin, and alternative treatments, like direct thrombin inhibitors. Dr. Maier is an Assistant Professor in the Department of Pathology and Laboratory Medicine at Emory University and the Medical Director of the Emory Special Coagulation Laboratory in Atlanta, Georgia.
Guest: Michael Gonzalez, PhD, MSc
New research on the molecular mechanisms behind idiopathic multicentric Castleman disease (iMCD) through gene expression analysis of lymph node tissue has the potential to improve both diagnosis and treatment. Join Dr. Michael Gonzalez as he dives in on his recent findings, which he spoke about at the 2024 American Society of Hematology Annual Meeting. Dr. Gonzalez is the Associate Director of Basic and Translational Research at the University of Pennsylvania Center for Cytokine Storm Treatment and Laboratory and an Adjunct Professor at La Salle University.
Guest: Mateo Bustamante
Idiopathic multicentric Castleman disease (iMCD) is a rare, life-threatening condition. Early diagnosis through excisional biopsies is key for speeding up treatment and improve patient outcomes. Learn more with Mateo Bustamante, a Senior Clinical Data Analyst at the Center for Cytokine Storm Treatment and Laboratory at University of Pennsylvania’s Perelman School of Medicine.
Guest: Joshua Brandstadter, MD, PhD, MSc
Castleman disease is difficult to diagnose and treat, with half of patients not responding to therapy. To address these challenges, Dr. Joshua Brandstadter discusses his research on how stromal cells play a role in the disease. Based at the University of Pennsylvania, Dr. Brandstadter is an Instructor of Medicine in the Division of Hematology and Oncology and the Director of Clinical Research for the Center of Cytokine Storm Treatment and Laboratory.
Host: Matt Birnholz, MD
The SIMPLIFY-2 trial compared the efficacy of momelotinib to best available therapy, which was primarily continued ruxolitinib, in patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor. According to the findings, momelotinib potentially offers better outcomes and a more comprehensive management strategy by addressing the underlying molecular mechanism of anemia. Learn more about the trial design and results with Dr. Matt Birnholz.
Guest: Betsy O'Donnell, MD
Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr. Elizabeth O’Donnell, Director of Early Detection and Prevention at Dana-Farber.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua E. Reuss, MD
The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center.
Host: Saad Z. Usmani, MD, MBA, FACP
Guest: Joshua Richter, MD
Guest: Ashley Steinberger, APP
Release date: 8/15/2024
Expiration date: 8/15/2025
Estimated time to complete: 1.0 hour
This activity is not accredited for CME/CE credit.
This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs).
The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christopher Chambers, MD
Guest: Adam H. Buchanan, MS, MPH
Since multi-cancer early detection (MCED) testing is a new technology, there’s been some discussion in the field about the impact it may have on patients, especially in terms of potential psychological harm like anxiety related to positive test results and false positive test results. Joining Dr. Charles Turck to discuss findings from a recent qualitative survey and the DETECT-A study focusing on how MCED testing may impact patient anxiety are Dr. Christopher Chambers and Mr. Adam Buchanan. Dr. Chambers is a Professor and Director of Clinical Trials at Thomas Jefferson University in Philadelphia, and Mr. Buchanan is an Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania.
Host: Jody Takemoto, PhD
Guest: David Braun
Identifying biomarkers for renal cell carcinoma (RCC) is critical since they can help direct our therapeutic approach, which is why several techniques that may be able to uncover new biomarkers are currently being investigated. Joining Dr. Jody Takemoto to review those techniques and their potential impacts on RCC care is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Host: Jody Takemoto, PhD
Guest: David Braun, MD, PhD
A recent study investigated whether renal cell carcinoma (RCC) molecular subtypes have any impact on treatment outcomes. Here to share the surprising findings and their implications is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That’s why a team with the HCC Steering Committee of the Chronic Liver Disease Foundation developed a web-based, interactive tool that incorporates current guideline recommendations to help clinicians diagnose and treat patients with hepatocellular carcinoma. To learn more about this tool, Dr. Jody Takemoto speaks with Dr. Robert Wong. Not only is he a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine, but he also helped develop the tool.
Host: Jesus G. Berdeja, MD
Guest: Nicholas G. Barkemeyer, MPAS
Guest: Ajai Chari, MD
Guest: Harvey Church
Guest: Amy Gebhardt
Guest: Steven Morrow
This activity is not accredited for CME/CE credit.
This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
Host: Matt Birnholz, MD
Guest: Saad Kenderian M.B, Ch.B
CAR T-cell therapy has been revolutionary in the treatment of blood cancers like chronic lymphocytic leukemia and multiple myeloma, and according to recent research, this therapeutic approach may also help patients with thyroid cancer. However, there are several challenges associated with applying this technology to target solid tumors in thyroid cancer, like tumor heterogeneity and resistance. Joining Dr. Matt Birnholz to talk about these challenges and how a research team is working to overcome them is Dr. Saad J. Kenderian, Assistant Professor of Oncology, Immunology, and Medicine at the Mayo Clinic in Rochester, Minnesota.
Guest: Elizabeth Montgomery, MD
Guest: John L. Marshall, MD
This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing, benefits of tissue versus liquid biopsy, when to test and why, and the use of biomarkers in prediction and prognosis. Finally, individualizing the treatment of mCRC based on molecular (eg, RAS, BRAF, MSI-high, HER2), patient (eg, comorbidities, age), and tumor (location, resectability) characteristics, as well as patient preferences (quality of life, treatment toxicities) will be discussed.
Host: Brian P. McDonough, MD, FAAFP
Guest: Betsy O'Donnell, MD
Guest: Tomasz Beer, MD, FACP
Should a patient get a positive multi-cancer early detection (MCED) test result, there are two diagnostic resolution pathways proposed for localizing and confirming that result. Joining Dr. Brian McDonough to break down those two pathways and how we can optimize our approach to diagnostic resolution are Drs. Betsy O’Donnell and Tom Beer. Dr. O’Donnell is the Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute, and Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
Hepatitis B is one of the leading causes of liver cancer globally, underscoring the importance of screening, diagnosing, and treating patients appropriately. However, there are several considerations to keep in mind when caring for patients with hepatocellular carcinoma with hepatitis B co-infection, which is why Dr. Jody Takemoto speaks with Dr. Robert Wong about those factors and essential management strategies. Dr. Wong is a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine.
Guest: Phillip H. Kuo, MD, PhD
One of the major changes that's occurred very recently in the field of neurodegenerative disease and Alzheimer's disease, specifically, are the recently approved antibody therapies that remove amyloid from the brain, which is one of the culprit proteins in Alzheimer's disease. To learn more about this presentation from SNMMI 2024, join Dr. Phillip Kuo, Professor of Medical Imaging, Medicine, and Biomedical Engineering at the University of Arizona.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
A recent study explored clinician-level gaps and barriers to hepatocellular carcinoma surveillance in patients with cirrhosis and found that there is a lot of work to be done to help improve knowledge about cirrhosis, the recommended cancer screening guidelines, and how to implement those recommendations. Joining Dr. Jody Takemoto to discuss these findings and how we can address the uncovered challenges is Dr. Robert Wong, Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine.
Host: Jennifer Caudle, DO
Guest: Patricia A. Mangan, RN, MSN, APRN-BC
The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting.
Guest: Geoffrey B. Johnson, M.D., Ph.D.
When looking at patients who suffer from prostate cancer who are receiving PSMA therapy, we can see on our images that the medication not only goes to their cancer, but it also goes to some other things in their body, including the salivary glands. To learn more about his recent study on salivary toxicity, join Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
Host: Jennifer Caudle, DO
Guest: Geoffrey B. Johnson, M.D., Ph.D.
Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it’s going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
Guest: Chi Liu, PhD
The field of artificial intelligence in nuclear medicine is evolving quickly with new models and approaches. Tune in with Dr. Chi Liu, Professor of Radiology and Biomedical Engineering at Yale University, to hear more about his presentation from SNMMI 2024.
Guest: Geoffrey B. Johnson, M.D., Ph.D.
Clinicians are hopeful that theranostics could help treat patients as soon as they go metastatic or even before surgery to try to affect their therapy and possibly get them to avoid having to take toxic or high side effect therapies. To hear more, tune in with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
Guest: Brianna Cagle
The Discovery Team at Perspective has developed a compound, called PSV-359, which is a cyclic peptide radiopharmaceutical. It targets a protein, called fibroblast activation protein (FAP), which is a pan-cancer target and is expressed in a wide variety of cancers. To learn more about her presentation from SNMMI 2024, hear from Brianna Cagle, Research Scientist at Perspective Therapeutics in Iowa.
Guest: Lillian Siu, MD, FRCPC
With a few studies in the works for cancer vaccines, the future is exciting for what this could mean for oncology patients. Dive in to learn about the various ways to package cancer vaccines so they can be delivered to patients effectively. And to learn more about the limitations, targets, and platforms of cancer vaccines, which was the topic of her presentation at the American Society of Clinical Oncology 2024 Conference, hear from Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto.
Host: Brian P. McDonough, MD, FAAFP
Guest: Nima Nabavizadeh, MD
Guest: Tomasz Beer, MD, FACP
While multi-cancer early detection (MCED) testing has the potential to significantly impact the way we approach cancer screening, it’s important to be aware of the risks associated with it, like overdiagnosis. That’s why Drs. Nima Nabavizadeh and Tom Beer join Dr. Brian McDonough to discuss the advantages and drawbacks of MCED testing and how we can mitigate the risk of overdiagnosis. Dr. Nabavizadeh is an Associate Professor in the Department of Radiation Medicine in the School of Medicine at OHSU in Portland, Oregon, and Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Guest: Lillian Siu, MD, FRCPC
Since cancer vaccines have been of interest to oncologists for decades, they’ve been trying to figure out how to prime or stimulate the immune system to attack cancer, and until the last few years, cancer vaccines have been challenging. To learn about this unique area of study, which she also presented at ASCO 2024, join Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto.
Guest: Ashley L. Sumrall, MD
If we want to ensure that we and our patients have healthcare when we’re older and it continues to be available, it’s important to take a stand and be a part of advocacy work. There are multiple ways to get involved, and it’s not as intimidating as someone might think, so to share some of these strategies and the impact it could have on the future of healthcare, join Dr. Ashely Sumrall, Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
Guest: Ashley L. Sumrall, MD
Advocacy is rooted in patients telling their stories, and every patient can be an advocate to help and allow others to hear about their experience. This has also helped clinicians get the medicine they need for their patients. Dive in to hear how you can incorporate advocacy strategies into your practice with Dr. Ashley Sumrall, Neuro- and Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
Guest: Tyler J Bradshaw, PhD
In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more about these new technologies and imaging agents, join Dr. Tyler Bradshaw, Associate Professor in the Department of Radiology at the University of Wisconsin-Madison, who presented this topic at the SNMMI 2024 Annual Meeting.
Host: Joseph Kim, MD, MPH
This video brief will discuss quality improvement in myelofibrosis management. To highlight ways to improve care for patients with both primary and secondary myelofibrosis, we’ll examine the experiences of two cancer centers that engaged in quality improvement programs.
- Molecular Testing
- Symptom Assessment
- Prognostic Risk Assessment
- JAK Inhibitor Therapy
- Shared Decision-Making
- Interprofessional Team-Based Care Coordination
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
- Gormley M, et al. Br Dent J. 2022;233(9):780-786.
- Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024
Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
Host: Brian P. McDonough, MD, FAAFP
Guest: Frank Diehl, PhD
A poster presented at the 2024 American Association for Cancer Research Annual Meeting showcased findings from the ASCEND 2 study, which examined the performance of a multi-cancer early detection (MCED) test design that included methylation and protein biomarkers. The study found that this test design achieved overall sensitivity of 50.9 percent for all cancers at a high specificity of 98.5 percent. Dive further into these results and what they might mean for early cancer detection with Dr. Brian McDonough and Dr. Frank Diehl, Senior Vice President of Multi Cancer Early Detection at Exact Sciences Corporation.
Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Justin Arnall, PharmD, BCOP, CPP
Guest: Jerry L. Spivak MD, MACP
While managing patients with myelofibrosis, there are certain indications that it may be time to switch therapies. And working with your patient will help with a timely and seamless transition. To learn more about these best practices, join Dr. Charles Turck as he speaks with Dr. Justin Arnal, Clinical Coordinator of Hematology at Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, and Dr. Jerry Spivak, Emeritus Professor Medicine at the Johns Hopkins University School of Medicine.
Guest: Justin Arnall, PharmD, BCOP, CPP
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jerry L. Spivak MD, MACP
After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to select the best intervention. Having a personalized approach to treatment and management could have a beneficial impact on the overall quality of life of your patient. Tune in with Dr. Charles Turck for insights and experiences from real-life patient cases with Dr. Justin Arnal, Clinical Coordinator of Hematology at Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, and Dr. Jerry Spivak, Emeritus Professor of Medicine at Johns Hopkins University School of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Prithviraj Bose, MD
Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.
Host: Jennifer Caudle, DO
Guest: Jason Tremblay
Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we’re using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.
Host: Jennifer Caudle, DO
Guest: Jason Tremblay
Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this disease is Dr. Jennifer Caudle who will be speaking with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Tara Graff, DO, MS
The therapeutic landscape for relapsed or refractory B-cell lymphoma has greatly evolved in the past several years, with CAR T-cell therapy and personalized care becoming increasingly important in the second-line setting. Joining Dr. Charles Turck to discuss how CAR T-cell therapy and patient-centered care can help optimize outcomes in the second-line treatment of patients with B-cell lymphoma is medical oncologist Dr. Tara Graff.
Guest: Matthew Lunning, DO, FACP
It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges and unmet needs exist in this setting, which is why Dr. Matthew Lunning is here to discuss those challenges as well as the novel therapies that are helping us overcome them. Dr. Lunning is an Associate Professor in the Division of Hematology and Oncology at the University of Nebraska Medical Center.
Host: Jennifer Caudle, DO
Guest: Sarah Rutherford, MD
Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell therapy with Dr. Jennifer Caudle and Dr. Sarah Rutherford, Assistant Professor of Medicine in the Division of Hematology-Oncology at Weill Cornell Medicine.
Guest: Alan Bryce, MD
Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neeraj Agarwal, MD, FASCO
TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a 37 percent reduction in risk of progression or death among those who received enzalutamide plus talazoparib. Dive further into the findings and their implications for patients with mCRPC with Dr. Charles Turck and Dr. Neeraj Agarwal, Professor of Medicine at the Huntsman Cancer Institute at the University of Utah.
Host: Rishi Sekar, MD
A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in the area. Dive further into the results with Dr. Rishi Sekar, who presented the “Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations” session at the 2024 ASCO Genitourinary Cancers Symposium.
Host: Jacob Sands, MD
Guest: Aakesh Desai, MD, MPH
According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr. Aakash Desai, an Assistant Professor of Medicine at the O’Neal Cancer Center at the University of Alabama at Birmingham.
Host: Zachery Reichert MD, PhD
If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with Dr. Zachery Reichert, who presented the “Sequencing Hormonal Therapies After Treatment Intensification” session at the 2024 ASCO Genitourinary Cancers Symposium.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Tomasz Beer, MD, FACP
Guest: Betsy O'Donnell, MD
Recent estimates show that only 14 percent of cancers are detected through routine screening, meaning the majority of patients are diagnosed after the onset of clinical symptoms. But multi-cancer early detection (MCED) tests offer the opportunity to potentially expand our ability to detect cancer through a single blood draw. Explore how MCED tests might help bridge the gaps that exist in today’s cancer screening paradigm and the recent studies on these tests with Drs. Tom Beer and Betsy O’Donnell. Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation, and Dr. O’Donnell is the Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.
Guest: Jessica E. Hawley M.D. M.S.
For patients who start out with hormone sensitive prostate cancer, there's a period of time where the prostate cancer cells are responsive to suppressing testosterone production. So there’s a nice disease response early in that time period after diagnosis and when initial treatment has begun, but how long is each patient going to respond to that initial treatment, and what role does the multidisciplinary team have? Dive in with Dr. Jessica Hawley, Medical Oncologist at Fred Hutch Cancer Center and an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine.
Host: Daniel Kwon, MD
Between patient anxiety and insurance implications, there are several challenges associated with delivering germline testing to veterans with advanced prostate cancer. Learn more about these challenges and proposed solutions with Dr. Daniel Kwon, who presented the “Challenges in Patient-Centered Germline Testing Delivery for Veterans with Advanced Prostate Cancer” session at the 2024 ASCO Genitourinary Cancers Symposium.
Guest: Jessica E. Hawley M.D. M.S.
The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.
Host: Neal Shore, MD
Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Ravi Rajaram, MD, MSC
NEOSTAR is a phase 2 trial with multiple arms looking at different combination therapies in the setting of resectable lung cancer. So what results were found from this study? Join in as Dr. Charles Turck discusses this further with Dr. Ravi Rajaram, Assistant Professor and the Clinical Medical Director in the Thoracic Center in the Department of Thoracic and Cardiovascular Surgery, Division of Surgery, at the University of Texas MD Anderson Cancer Center in Houston.
Host: Jacob Sands, MD
Guest: Liza Villaruz, MD
According to a recent study, the immune checkpoint inhibitor durvalumab is not only considered safe, but it may also offer overall survival benefits for individuals with advanced or metastatic non-small cell lung cancer (NSCLC) and restricted performance status. Here to talk about this research are Dr. Jacob Sands and Dr. Liza Villaruz, Associate Professor of Medicine at the University of Pittsburgh School of Medicine.
Host: Adam Brufsky, MD, PhD
Host: Christopher M. Gallagher, MD
Join us as expert faculty, Dr. Adam Brufsky and Dr. Christopher Gallagher, discuss the qualities of credible real world evidence (RWE) publications, application of CDK4/6 inhibitor RWE in hormone receptor positive metastatic breast cancer, and integrating RWE into everyday clinical decision and shared decision making conversations. This 15-minute activity provides a practical discussion to increase clinician familiarity and comfort with RWE of CDK4/6 inhibitors in metastatic breast cancer and clinicians’ confidence in their ability to discuss RWE with their patients.
Guest: Filipa Lynce, MD
Inflammatory breast cancer (IBC) is a rare disease that represents about two to three percent of all breast cancers and is challenging to diagnose. To improve diagnosis, researchers are working to validate a new proposed scoring system. Review the current research with Dr. Flipia Lynce, Director of the Inflammatory Breast Cancer Program at the Dana Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.
Guest: Filipa Lynce, MD
It’s very common for patients with inflammatory breast cancer (IBC) to present with no underlying palpable mass, which may cause some challenges for clinicians and patients. So what are some unique challenges associated with surgery in IBC and the risks of deescalating? Join Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer Program at the Dana Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School, as she reviews her research on IBC that she presented at the 2023 San Antonio Breast Cancer Symposium.
Host: Pavani Chalasani, MD, MPH
Guest: Jason A. Mouabbi, MD
Invasive lobular carcinoma (ILC) is an understudied subtype that occurs in about 10 to 15 percent of breast cancer patients and is known to be difficult to detect by imaging. So how do we approach diagnosing and treating this subtype? Dr. Pavani Chalasani is joined by Dr. Jason Mouabbi, Assistant Professor of Medicine at the University of Texas MD Anderson Cancer Center and Chair of the Lobular Breast Cancer Alliance, to discuss his session on ILC at the 2023 San Antonio Breast Cancer Symposium.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Pavani Chalasani, MD, MPH
Acquired ESR1 mutations cannot be detected on archival tissue and require liquid biopsy. Fortunately, this approach circumvents the challenges of acquiring serial tissue while allowing for the real-time monitoring of ESR1 status in patients with metastatic breast cancer. Learn more about the rationale behind liquid biopsies and best practices for utilizing them in clinical practice with Dr. Charles Turck and Dr. Pavani Chalasani, Division Director of Hematology-Oncology at the GW Cancer Center in Washington, DC.
Guest: Mariya Rozenblit, MD
ESR1 mutations are frequently acquired during aromatase inhibitor treatment for HR+/HER2- metastatic breast cancer, making liquid biopsy monitoring vital to identify endocrine resistance. Learn more about this acquired mutation and how it can impact treatment with Dr. Mariya Rozenblit, Assistant Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine.
Host: Pavani Chalasani, MD, MPH
Guest: Marcela Mazo Canola, MD
Recent studies have examined the implications of ESR1 mutations in metastatic breast cancer and found that ESR1 mutations predict poor response to subsequent endocrine therapy. These acquired mutations also correlate with aggressive disease and, by extension, worse prognosis. Dive further into these findings from various studies and how they might impact the way we treat patients with metastatic breast cancer with Dr. Pavani Chalasani and Dr. Marcela Mazo Canola, Assistant Professor at UT Health San Antonio’s Mays Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Stephanie Graff, MD
Guest: Pavani Chalasani, MD, MPH
When treating patients with metastatic breast cancer, it’s important to repeatedly conduct liquid biopsies to look for acquired ESR1 mutations when patients progress after endocrine therapy, even if initial testing was done. That’s why Dr. Charles Turck is breaking down best practices for utilizing liquid biopsies to detect ESR1 mutations with Drs. Stephanie Graff and Pavani Chalasani. Dr. Graff is the Director of Breast Oncology at the Lifespan Cancer Institute in Providence, Rhode Island, and Dr. Chalasani is the Division Director of Hematology-Oncology at the GW Cancer Center in Washington, DC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Justin Taylor, MD
A recent study sought to determine whether CNS treatment or prophylaxis combined with systemic tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) impacts patient prognosis and the efficacy of tagraxofusp. According to the results presented as a poster at the 2022 European Hematology Association Annual Congress, treatment with tagraxofusp and intrathecal chemotherapy was associated with promising efficacy in patients with CNS disease, with no unexpected safety events. Joining Dr. Charles Turck to share the key findings and how they may impact the way we approach treating patients with BPDCN is Dr. Justin Taylor, Assistant Professor of Hematology at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine.
Guest: Megan Kruse, MD
While intrinsic mutations, like PIK3CA, are present at the outset and can be identified upfront in patients with HR+/HER2- metastatic breast cancer, acquired mutations, like ESR1, cannot be detected on baseline tumor profiling. That’s why longitudinal monitoring with liquid biopsies over the course of treatment is required. Learn more about these key differences in testing for acquired versus intrinsic mutations with Dr. Megan Kruse, a breast medical oncologist at the Cleveland Clinic.
Host: Pavani Chalasani, MD, MPH
Guest: Jose Pablo Leone, MD
Breast cancer is the second most common cause of brain metastases. Given this prevalence, how can we identify the early signs and symptoms and treat patients with metastatic breast cancer accordingly? Here to dive further into this topic with Dr. Pavani Chalasani is Dr. Jose Pablo Leone, Director of the Program for Breast Cancer in Men at Dana-Farber.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Sophia Humphreys, PharmD, MHA, BCBBS
Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary Katherine Cheeley is Dr. Sophia Humphreys, Director of System Pharmacy Formulary Management and Clinical Programs at Sutter Health.
Host: Pavani Chalasani, MD, MPH
Guest: Gabriel N. Hortobagyi, MD
Bone metastases are the most frequent site of metastatic spread for breast cancer, especially for the luminal subtypes, which are the most frequent types of breast cancer. Here to dive further into these therapies with Dr. Pavani Chalasani is Dr. Gabriel Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology in the Division of Cancer Medicine at the University of Texas, MD Anderson Cancer Center in Houston.
Host: Pavani Chalasani MD, MPH
Guest: Nick McAndrew, MD, MSCE
How can ribociclib plus endocrine therapy help reduce recurrence in early breast cancer? That’s the exact question the NATALEE trial sought to answer, and here to discuss the results with Dr. Pavani Chalasani is Dr. Nicholas McAndrew, Assistant Professor in the Division of Hematology and Oncology at the UCLA David Geffen School of Medicine.
Host: Jacob Sands, MD
Guest: Jia Luo, MD
NUT carcinoma is a rare, aggressive form of cancer that’s highly resistant to therapy and has no defined standard treatment. Joining Dr. Jacob Sands to discuss the best diagnostic and treatment strategies for NUT carcinoma is Dr. Jia Luo, medical oncologist at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School in Boston.
Host: Pavani Chalasani MD, MPH
Guest: Colleen Bohnenkamp, PharmD, BCPS, BCOP
In a recent study, investigators conducted a randomized trial to compare the efficacy and tolerability of a fixed dose of an oral chemotherapy drug on a 7/7 schedule. Here with Dr. Pavani Chalasani to discuss the results from the X-7/7 trial is Dr. Colleen Bohnenkamp, Oncology Clinical Pharmacist who specializes in women’s cancers at the University of Kansas Cancer Center.
Host: Harry Paul Erba, MD, PhD
Guest: Courtney DiNardo, MD
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Richard T. Penson, MD, MRCP
Uterine cancer is the most common type of gynecologic malignancy in the United States, and disease mortality is on the rise. What do we need to know from recent studies to diagnose patients earlier? Take a deep dive with Dr. Charles Turck as he is joined by Dr. Richard Penson, Medical Oncologist specializing in Gynecologic Oncology at Massachusetts General Hospital in Boston.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Richard Kim, MD
Guest: Benjamin A. Weinberg, MD
Sadly, colon cancer is a very common cause of cancer-associated death in the United States. However, things may be looking up as data from ongoing trials is uncovered. Explore metastatic colorectal cancer (mCRC) further with Dr. Charles Turck as he speaks with Dr. Richard Kim, Service Chief of Medical Gastrointestinal Oncology at Moffitt Cancer Center in Tampa, Florida, and Dr. Benjamin Weinberg, Associate Professor of Medicine and Attending Physician specializing in Gastrointestinal Medical Oncology and Sarcoma at MedStar Health in Washington, DC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Priscilla Brastianos, MD
Brain metastases are the most common type of brain tumor, and unfortunately, prognosis is still limited and can range from a few months to a few years. However, the next-step approaches look promising for improving patient outcomes. Dive in with Dr. Charles Turck as he speaks with Dr. Priscilla Brastianos, Associate Professor of Medicine at Harvard Medical School and the Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital.
Since there are limited treatment options available for patients with refractory metastatic colorectal cancer (mCRC), the purpose of this global phase 3 cohort, called FRESCO-2, was to analyze the adverse events of a treatment. Tune into this segment to learn more about this study.
In the US, the first-line treatment for metastatic colorectal cancer (mCRC) is chemotherapy with FOLFOX/FOLFIRI. However, a different combination treatment could show promise for being a first-line therapy selection. Learn more from this presentation of the data.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Frank Diehl, PhD
A poster presented at the 2022 American Association for Cancer Research Special Conference on Precision Prevention, Early Detection, and Interception of Cancer found that a four-biomarker class multi-cancer early detection (MCED) test configuration had higher overall sensitivity and specificity compared to a three-biomarker test configuration. These results imply that more early-stage cancers could be detected. Dive further into the data and results with Dr. Charles Turck and Dr. Frank Diehl, Senior Vice President of Multi-Cancer Early Detection at Exact Sciences Corporation and co-author of the poster.
This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.
Guest: Vivek Subbiah, MD
This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.
Host: Jason J. Luke, MD, FACP
Guest: Tara Mitchell, MD
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
Guest: Alison Wakoff Loren, MD, MSCE
Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman School of Medicine.
Host: Jacob Sands, MD
Guest: Joseph O. Jacobson, MD
Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.
Host: Jacob Sands, MD
Guest: Aliyah Pabani, MD
Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Megan Kruse, MD
From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jacob Sands, MD
Guest: Joshua K. Sabari, MD
Obstacles with platinum rechallenge could lead to treatment burden, but a second-line alternative therapy could be a better option for some of our patients. To learn more, Dr. Charles Turck is joined by Drs. Jacob Sands and Joshua Sabari to share their insights on this therapy for patients with small cell lung cancer.
Host: Jacob Sands, MD
Guest: Biagio Ricciuti, MD
Treatment for lung cancer can be complex, but PL-L1 expression and tumor mutational burden might help us select the best treatment for our patients. What do we need to know about the role of these biomarkers in the treatment of lung cancer? To discuss this, Dr. Jacob Sands is joined by Dr. Biagio Ricciuti, a medical oncologist at the Dana-Farber Cancer Institute.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.
Host: Jacob Sands, MD
Guest: Eleni Rettig, MD
HPV is the leading cause of oropharynx cancers in the United States, but with no screening tools currently available, how we can detect this cancer in our patients? Host Dr. Jacob Sands speaks with a leader in the field, Dr. Eleni Rettig, an Assistant Professor of Otolaryngology-Head and Neck Surgery at Harvard Medical School, to share risk factors and explore emerging diagnostic tools.
Guest: Michelle Mollica, PhD, MPH, RN, OCN
Can cancer survivorship models help clinicians navigate the road ahead with their cancer patients? Here to share insights on unmet needs, opportunities, and symptom burden for cancer survivorship care is Dr. Michelle Mollica, the Deputy Director at the National Cancer Institute’s Office of Cancer Survivorship.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hope S. Rugo, MD, FASCO
The treatment landscape for metastatic breast cancer is rapidly evolving. With all of these new advancements and research, it can be helpful to review the available treatment options and best practices for selecting an approach after treatment with a CDK4/6 inhibitor has failed. That’s why Dr. Charles Turck discusses how we can treat patients with metastatic breast cancer in the second- and third-line setting with Dr. Hope Rugo, who’s a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Hellen Diller Family Comprehensive Cancer Center.
Guest: Lisa Parks, MS, APRN-CNP, ANP-BC
For some cancer patients undergoing surgery, prehabilitation care could impact their outcomes. So what do nurses need to consider in their preoperative assessment? And what key players are part of the multidisciplinary healthcare team? Lisa Parks from the Ohio State University Wexner Medical Center in Columbus, Ohio explores key factors for cancer surgery.
Guest: Lisa Parks, MS, APRN-CNP, ANP-BC
To learn more about key considerations for prehabilitation, Nurse Practitioner Lisa Parks from the Ohio State University Wexner Medical Center in Columbus, Ohio recaps important factors to keep in mind for cancer patients undergoing surgery.
Guest: Lisa Parks, MS, APRN-CNP, ANP-BC
When considering prehabilitation for cancer patients about to undergo surgery, what factors should we keep in mind? Nurse Practitioner Lisa Parks from the Ohio State University Wexner Medical Center in Columbus, Ohio explores some of the key considerations involved in prehabilitation.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Brian Mulherin, MD
It's not uncommon for years to elapse after a patient first develops symptoms of paroxysmal nocturnal hemoglobinuria (PNH) and before a formal diagnosis is made. So how does the burden of PNH affect patient outcomes? Dive in as Dr. Charles Turck is joined by Dr. Brian Mulherin, Hematology and Oncology Specialist at Hematology Oncology of Indiana.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hana Safah, MD
Guest: Timothy Kubal, MD
The most common way for clinicians to detect paroxysmal nocturnal hemoglobinuria (PNH) in a patient are signs of intravascular hemolysis. So how does this disorder impact a patient’s quality of life? Dive in as Dr. Charles Turck is joined by Dr. Kubal, Associate Member in the Moffitt Cancer Center Malignant Hematology Department in Tampa, Florida, and Dr. Safah, Professor of Clinical Medicine at the Tulane University School of Medicine in New Orleans.
Host: Ezra Cohen, MD, FRCPSC, FASCO
Guest: Petr Szturz, MD, PhD
While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.
For patients with ER+/HER2- advanced breast cancer, current treatment guidelines recommend the use of endocrine therapy plus a CDK 4/6 inhibitor as a first-line treatment. And while the guidelines recommend sequential endocrine therapy for disease progressions, this progression can lead to ESR1 mutations and resistance to endocrine therapy. Could a novel oral selective estrogen receptor have more efficacy in preventing ESR1 mutations associated with endocrine resistance? That’s the exact question the EMERALD trial sought to answer, and what this study found in its subgroup analyses is the focus of this Audio Abstract.
Host: Jennifer Caudle, DO
Guest: Stephanie Graff, MD
Guest: Pavani Chalasani MD, MPH
Given the challenges and unmet needs associated with the current treatment options for ER+/HER2- advanced breast cancer, what strategies can we use to optimize our approach? Here with Dr. Jennifer Caudle to share their perspectives are Dr. Stephania Graff from Lifespan Cancer Institute and Dr. Pavani Chalasani from the University of Arizona Cancer Center.
Host: Jennifer Caudle, DO
Guest: Nan Chen, MD
Selective estrogen receptor degraders (SERDs) are a novel class of drugs for the treatment of ER+/HER2- advanced breast cancer. So how exactly do they work to treat this type of advanced breast cancer, and what are the findings from recent trials investigating the clinical utility of SERDs? Get the answers to these and other key questions with Dr. Jennifer Caudle and Dr. Nan Chen, Assistant Professor of Medicine at the University of Chicago School of Medicine.
Host: Jennifer Caudle, DO
Guest: Stephanie Graff, MD
Endocrine resistance and toxicities are just a few of the many challenges facing clinicians who treat patients with ER+/HER2- advanced breast cancer. So what strategies can we use to better address these challenges and unmet needs? Joining Dr. Jennifer Caudle to share her approach is Dr. Stephanie Graff, Director of the Breast Oncology Program at Lifespan Cancer Institute in Providence, Rhode Island.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Mascarenhas, MD
Guest: Raajit Rampal, MD, PhD
What do we need to know about the therapeutic landscape and management of myelofibrosis-related anemia? Here to share their perspectives with Dr. Charles Turk are Dr. Raajit Rampal from the Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai.
Endocrine therapy is the recommended treatment for ER+/HER2- advanced breast cancer, but progression to advanced disease can lead to ESR1 mutations, which can then lead to endocrine therapy resistance. But could treatment with an oral selective estrogen receptor degrader (SERD) improve outcomes for our patients? Join us as we take a deep dive into the EMERALD trial, which explored that exact question, in this Audio Abstract.
Host: Wui-Jin Koh, MD
Join our top experts from around the world as they discuss evidence- and consensus-based recommendations from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), as well as the latest emerging clinical evidence in the optimal treatment of cancer. This multi-format, multispecialty, and multiregional educational initiative is designed to support your knowledge, competence, and skills across multiple solid tumor types.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Mascarenhas, MD
There are several challenges and limitations associated with the current therapeutic options available for myelofibrosis-related anemia, leading to a recent push to transform the treatment paradigm. Joining Dr. Charles Turck to share strategies for optimizing the care of patients with myelofibrosis-related anemia is Dr. John Mascarenhas, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Mount Sinai Tisch Cancer Center.
Host: Aaron Gerds, MD
There are two key unmet needs in the treatment of myelofibrosis. Here to share what those are and how we can work to address them is Dr. Aaron Gerds from the Cleveland Clinic.
Host: Srdan (Serge) Verstovsek, MD, PhD
Unfortunately, anemia is very prevalent among patients with myelofibrosis. Learn more about the impact of myelofibrosis-related anemia on patients and the clinicians treating them with Dr. Srdan Verstovsek, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.
Host: Jacob Sands, MD
Guest: Tomasz Beer, MD, FACP
Multi-cancer early detection tests are designed to detect multiple cancers from a single blood test. Could these tests help address some of the most common limitations associated with current cancer screening methods, like a lack of adherence and access? Joining Dr. Jacob Sands to discuss how multi-cancer early detection tests work and their potential impact on cancer screening is Dr. Tom Beer, Adjunct Professor of Medicine at the OHSU Knight Cancer Institute and the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: A. Mark Fendrick, MD
With the relaunch of the Cancer Moonshot initiative, implementing strategies to overcome disparities in cancer screening is critical to reducing the rate of cancer mortality. Dr. Charles Turck joins Dr. Mark Fendrick to explore these disparities, and discuss the role of multicancer detection tests.
Guest: Patrick Forde, MD
Guest: Jesús García-Foncillas, MD, PHD
Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!
Host: Pavani Chalasani MD, MPH
Guest: Hope S. Rugo, MD
Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.
Host: Janani Reisenauer, MD
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Lung cancer screenings have shown to be effective in detecting lung cancer earlier. So what are the current guidelines? To discuss this question and give their own experiences with lung cancer screenings and the management of early-stage lung cancer are expert pulmonologists, Drs. Septimiu Murgu and Janani Reisenauer. Dr. Murgu is from the University of Chicago, and Dr. Reisenauer is from the Mayo Clinic.
Host: Jacob Sands, MD
Guest: Edward B. Garon, MD, MS
Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Ehab L. Atallah, MD
New longer-term outcome data for chronic lymphocytic leukemia (CLL) has recently emerged with some interesting results. To dive into the key findings of these trials and other current CLL treatments available, Dr. Charles Turck is joined by Dr. Ehan Atallah, Professor of Medicine and the Section Head of Hematological Malignancies at the Medical College of Wisconsin Division of Hematology and Oncology.
Host: Pavani Chalasani MD, MPH
Guest: Prof. David Cameron
A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.
Host: Pavani Chalasani MD, MPH
Guest: Erika Hamilton, MD
A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Bethany Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.
Host: Pavani Chalasani MD, MPH
Guest: Kevin Kalinsky MD, MS
CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher, Dr. Kevin Kalinsky from the Winship Cancer Institute at Emory University.
Host: Pavani Chalasani MD, MPH
Guest: Nan Chen, MD
Immunotherapy is starting to make its way in breast cancer, especially triple-negative breast cancer. So how do we identify which of our patients are good candidates for this treatment? Joining Dr. Pavani Chalasani to share the most recent research on immunotherapy is Dr. Nan Chen, an Assistant Professor of Medicine at the University of Chicago.
Host: Pavani Chalasani MD, MPH
Guest: Seema A. Khan, MD
Dr. Pavani Chalasani meets with Dr. Seema Khan, a Professor of Surgery and Interim Co-Vice Chair of Research at Northwestern Feinberg School of Medicine, to explore the role of surgery in metastatic breast cancer and take a look at the current treatment landscape.
Host: Jacob Sands, MD
Guest: Maya Leiva, PharmD, BCOP
What causes drug shortages in the U.S.? Joining Dr. Jacob Sands to answer this question and dive in to what physicians and pharmacists can do to prepare for future shortages is Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.
Host: Jacob Sands, MD
Guest: Maya Leiva, PharmD, BCOP
Recognizing bias and improving diversity is critical for patient outcomes, especially within the field of oncology. To explore how we can improve care for both LGBTQ+ patients and employees within healthcare, Dr. Jacob Sands is joined by Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.
HER2 (ERBB2) mutations may increase receptor internalization and lead to hyperactive downstream signaling, uncontrolled cell growth, and tumorigenesis. Learn more about how HER2 mutations affect several types of cancer, including non-small cell lung cancer (NSCLC).
Intended for US Healthcare Professions only
©2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1332 06/22
Host: Pavani Chalasani MD, MPH
Guest: Kevin Kalinsky MD, MS
Chemotherapy is one of the most commonly used treatments for cancer—but it can lead to challenging side effects. So do all of our patients really need it? Joining Dr. Pavani Chalasani to discuss whether or not chemotherapy is the right choice for patients with hormone receptor-positive HER2-negative, node-positive breast cancer is Dr. Kevin Kalinsky from Emory University.
Host: Jacob Sands, MD
Guest: Marie Wood, MD
Can our breast cancer patients benefit from chemoprevention? Joining Dr. Jacob Sands to share treatment options for chemoprevention and which patients may benefit the most is Dr. Marie Wood, the Director of Breast Medical Oncology and Director of the Cancer Clinical Trials Office at the University of Colorado Anschutz Medical Center.
Host: Pavani Chalasani MD, MPH
Guest: Aditya Bardia, MD, MPH
For patients with hormone receptor-positive HER 2-negative metastatic breast, treatment can be challenging. But what treatment options are available? Lead investigator from the EMERALD trial Dr. Aditya Bardia joins Dr. Pavani Chalasani to share his insights.
Host: Pavani Chalasani MD, MPH
Guest: Aditya Bardia, MD, MPH
Triple-negative breast cancer can be a challenging battle for patients, especially when it comes to treatment. And that's why the ASCENT trial dove into the treatment landscape for these patients. Lead investigator of this trial, Dr. Aditya Bardia, sits down with Dr. Pavani Chalasani for an inside look at this trial and what it means for patients with triple-negative breast cancer.
Host: Jacob Sands, MD
Guest: Manish A. Shah, MD FASCO
For patients with unresectable liver-limited hepatocellular carcinoma, treatment can be challenging. Clinicians typically care for these patients with local-regional therapies, but is that the best option for all of them? To answer this question, Dr. Jacob Sands joins Dr. Manish Shah from Weill Cornell Medicine to take a look at current and emerging strategies for managing and treating unresectable liver-limited hepatocellular carcinoma.
Host: Jacob Sands, MD
Guest: Edith Mitchell, MD, MACP, FCPP, FRCP
Appointed member to the President's Cancer Panel and Clinical Professor of Medicine at Thomas Jefferson University, Dr. Edith Mitchell, shares what the panel recommends to close gaps in cancer screening in the U.S.—with a focus on colorectal cancer—to improve access for all patients.
Host: Jacob Sands, MD
Guest: Edith Mitchell, MD, MACP, FCPP, FRCP
Widespread health disparities have led to challenges in colorectal cancer screening. What's causing these disparities—and what are some ways we can overcome these obstacles? To dive into this topic, Dr. Jacob Sands is joined by Dr. Edith Mitchell from Thomas Jefferson University to discuss these disparities and how they may be impacting clinical outcomes.
Guest: Claresa Levetan, MD
How can we better communicate lifestyle changes and glucose monitoring levels with our diabetic patients? Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares key communication strategies she uses with her patients.
Host: Jacob Sands, MD
Guest: Daniel Sessler, MD
Our choice of anesthesia, whether it's regional or general, can have an effect on the outcome of our patients. But can this decision also contribute to cancer recurrence? To understand this, Dr. Jacob Sands sits down with renowned researcher in the anesthesia community, Dr. Dan Sessler, to learn more about his research on the impacts of general anesthesia.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Maryam Lustberg, MD, MPH
Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.
Host: Jacob Sands, MD
Guest: Kathleen Fenn, MD
Guest: Oudai Hassan, MD
How do the 2018 ASCO/CAP guidelines redefine our approach to caring for patients with HER2-mutated breast cancer? Find out as Dr. Jacob Sands speaks with Dr. Kathleen Fenn and Dr. Oudai Hassan about HER2 scoring criteria and how the data drives collaborative care between the medical oncology and pathology teams.
Guest: Alexander Spira, MD, PhD, FACP
When it comes to HER2 mutations in non-small cell lung cancer (NSCLC), there’s a lot to consider, like CNS metastases, current therapies, patient characteristics, and more. That’s why Dr. Alexander Spira from Johns Hopkins is here to give us an essential overview of HER2 mutations in NSCLC.
Guest: Pavani Chalasani MD, MPH
What were the key findings from the EMERALD, Destiny-03, and PADA 1 trials that were featured at the 2021 San Antonio Breast Cancer Symposium? Explore the data on emerging breast cancer therapies with Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology and Oncology Fellowship at the University of Arizona Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua Richter, MD
Here to share his perspective on the use of triplet therapy for the treatment of multiple myeloma is Dr. Joshua Richter. Dr. Richter shares a patient case and speaks with Dr. Charles Turck about why this treatment may be an option for some patients.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Pediatric and adolescent oncofertility patients are cared for differently than adult patients. That’s why Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital, is here to give us an overview of the available procedures for pediatric patients and the key considerations that go along with them.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Cancer treatment can impact fertility outcomes for individuals throughout the U.S. as well as around the globe, which is why the emerging field of oncofertility is here to help male and female patients navigate their fertility options before and after their cancer treatments. So what can we learn from oncofertility services and efforts from other countries around the world? Joining Dr. Jacob Sands to share her global viewpoints on the field of oncofertility is Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital.
Host: Jennifer Caudle, DO
Guest: Maryam Lustberg, MD, MPH
Developing a coordinated survivorship care plan between oncologists and primary care physicians is a top priority for cancer patients. To better understand what goes into this, Dr. Jennifer Caudle is joined by Dr. Maryam Lustberg, Director of The Breast Cancer Center at the Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, to discuss the role of the primary care physician in survivorship care for breast cancer patients.
Guest: Pavani Chalasani MD, MPH
Has our understanding of HER2 status changed? Dr. Pavanai Chalsani from the University of Arizona Cancer Center dives into the reclassification of HER2 status and shares emerging clinical trial data.
Guest: Terry P. Mamounas, MD
What do we need to know about the management of the axilla for patients with early-stage breast cancer? Dr. Terry Mamounas shares highlights from his presentation at the 2021 San Antonio Breast Cancer Symposium titled, “Refining Axillary Management After Neoadjuvant Chemotherapy - What Does the Evidence Support?”
Guest: Steven J. Chmura, MD, PhD
What do we need to know about the ablation of oligometastatic disease? Dr. Steven J. Chmura shares his vantage point on this topic and others from the 2021 San Antonio Breast Cancer Symposium.
Guest: Timothy Yap, MBBS, PhD, FRCP
As DNA damage response therapies move beyond PARP inhibitors, what do we need to know? Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares insights and takeaways from his presentation at the 2021 San Antonio Breast Cancer Symposium.
Guest: Timothy Yap, MBBS, PhD, FRCP
With a lack of clear standards of care in the post CDK4/6 inhibitor setting, a new study aims to address this unmet need. Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares clinical trial data and its impact on cancer patients.
Host: Jacob Sands, MD
Guest: Millie Das, MD
Getting a better understanding of your patient’s challenges might help you improve their care and streamline the path from diagnosis to treatment. To better understand this, Dr. Jacob Sands sits down with Dr. Millie Das from the Stanford School of Medicine to share strategies to choose the best course of care.
Host: Joël Guigay, MD, PhD
Guest: Kevin J. Harrington, MD
Formulating individualized treatment plans for patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) is increasingly essential and increasingly complex. Newer regimens have become the standard of care because of their efficacy in overall survival and reduced toxicities. So how do we deploy them now that they’re in our treatment armamentarium?
Join Drs. Joël Guigay and Kevin Harrington as they explore the role of IO as the standard of care in SCCHN and discuss the potential of taxanes to reduce dependence on fluorouracil-based chemotherapeutic regimens. Tune in to make sure you’re meeting the needs of your patients’ with SCCHN.
Host: Jacob Sands, MD
Guest: Suneeta Senapati, MD, MSCE
Guest: Mindy Christianson, MD
Patients undergoing treatments such as chemotherapy may be at significant risk of impairment or inability to have children later in life. This risk impacts both men and women equally, but fortunately, the field of oncofertility can help guide patients as they navigate their fertility options prior to cancer treatment. Here to share their insights on this emerging field with Dr. Jacob Sands are Dr. Mindy Christianson and Dr. Suneeta Senapati.
Guest: Michael Wang, MD
What can we look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Michael Wang shares anticipated updates in mantle cell lymphoma, or MCL.
Guest: Daniel O. Persky, MD
From updates in combination therapy to developments in novel agents, Dr. Daniel Persky shares what he expects to see for chronic lymphocytic leukemia and mantle cell lymphoma from the American Society of Hematology’s 63rd Annual Meeting and Exposition.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew H. Lipsky, MD
Dr. Charles Turck is joined by Dr. Andrew Lipsky to examine the mechanisms contributing to acquired resistance in CLL and MCL targeted therapies and outline strategies to prevent this resistance.
Host: Jacob Sands, MD
Guest: Tejas Patil, MD
What kind of role does next-generation sequencing play in HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Tejas Patil from the University of Colorado Medicine to explore the clinical utility of NGS and highlight opportunities to expand molecular testing into clinical practice.
Guest: Howard (Jack) West, M.D.
For patients with advanced non-small cell lung cancer, broad molecular testing can be both a solution and a challenge. Here to share key challenges for next-generation sequencing is Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center in California.
Guest: John C. Byrd, MD
For patients with chronic lymphocytic leukemia, molecular analysis can provide critical information. Dr. John C. Byrd discusses the importance of IGHV and TP53 sequencing and the clinical value they provide.
Guest: Lindsey Roeker, MD
As the field of chronic lymphocytic leukemia continues to evolve, what we can look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Lindsey Roeker shares what she expects to see at this year’s ASH meeting.
Host: Mark Socinski, MD
Guest: John V. Heymach, MD, PhD
FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Thomas Kipps, MD, PhD
What do the NCCN guidelines recommend for the management of patients with chronic lymphocytic leukemia, or CLL, and mantle cell lymphoma, or MCL? Dr. Charles Turck is joined by Dr. Thomas Kipps to talk about prognostic risk indicators, current therapeutic agents, and adverse events for patients with CLL and MCL.
Host: Hector O. Chapa, MD, FACOG
Guest: Sandra Misale, MD
As the treatment landscape continues to evolve, what do we need to know about current treatment challenges and novel therapeutic options? Dr. Hector Chapa is joined by Dr. Sandra Misale to explore emerging therapies in HER2-mutated non-small cell lung cancer.
Guest: Banu Arun, MD
Here to give highlights from the “Finetuning Risk Assessment and Risk Reduction” session at the 2021 San Antonio Breast Cancer Symposium (SABCS) is Dr. Banu Arun, Professor of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center and Executive Director of Cancer Genetics for the MD Anderson Cancer Networks.
Guest: Nicolas Girard, MD
Guest: Alex Spira, MD, PhD, FACP
While the management and treatment of HER2-mutated non-small cell lung cancer continues to evolve, patients still face many unmet needs. Dr. Nicolas Girard, a pneumologist and Professor of Respiratory Medicine at Versailles Saint Quentin University, explores these unmet needs and how we can solve them.
Host: Jacob Sands, MD
Guest: Nicole Lamanna, MD
When determining a patient’s therapy regimen, what disease-related factors do we need to keep in mind? Dr. Nicole Lamanna, a Hematologist/Oncologist at Columbia University Medical Center, share strategies for tailoring chronic lymphocytic leukemia treatment and how that can impact patient outcomes.
Guest: Thomas Kipps, MD, PhD
Has the COVID-19 pandemic limited our treatment options for patients with mantle cell lymphoma? To answer this, Dr. Thomas Kipps reviews key treatment challenges and considerations for these patients amid the ongoing pandemic.
Host: Hector O. Chapa, MD, FACOG
Guest: Sandra Misale, MD
Did you know that HER2 mutations can be found in about 4 percent of patients with non-small cell lung cancer (NSCLC)? Although it’s not a very common genetic event, it’s still important to know how these mutations drive disease progression and how you can treat these NSCLC patients. That’s why Dr. Sandra Misale joins Dr. Hector Chapa to explore the clinical features and characteristics of HER2 mutations along with the available therapeutic options.
Host: Nabil F. Saba, MD
Couldn’t attend the 2021 European Society of Medical Oncology (ESMO) Conference? No worries—ReachMD host Dr. Nabil Saba is here to share the latest updates in head and neck cancer from the 2021 ESMO Conference.
Host: Jacob Sands, MD
Guest: Howard (Jack) West, MD
Guest: Nicolas Girard, MD
How can we better diagnose and treat patients with HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Nicolas Girard and Dr. Jack West to explore diagnostic and therapeutic challenges and share collaborative patient management strategies for these patients.
Host: Jacob Sands, MD
Guest: Joseph Tuscano, MD
While lymphoma can sometimes be difficult to treat, emerging therapies and clinical developments are on the horizon. But could they help improve patient outcomes? Dr. Jacob Sands is joined by Dr. Joseph Tuscano, Physician and Professor of Hematology and Oncology at UC Davis Comprehensive Cancer Center to talk about updates in Lymphoma treatment.
Host: Jennifer Caudle, DO
Guest: Lindsey Roeker, MD
From causes to counseling strategies, Dr. Lindsey Roeker joins Dr. Jennifer Caudle to dive into chronic lymphocytic leukemia fatigue and how we can help our patients who are experiencing this kind of fatigue.
Host: Scott Kopetz, MD, PhD
Guest: Rona Yaeger, MD
Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.
This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.
Guest: Alexander Spira, MD, PhD, FACP
The 2021 ESMO Congress featured a lot of new advancements in non-small cell lung cancer (NSCLC) treatment. Here to provide a recap of one of those treatments for NSCLC patients with HER2 mutations is Dr. Alexander Spira, Co-Director of the VCS Research Institute, Director of the Thoracic and Phase I Program, and Clinical Assistant Professor at Johns Hopkins.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Joshua Ofman, MD, MSHS
Despite significant advancements in therapeutics, the oncology community has not yet been able to declare victory in the “war on cancer.” In fact, about 40 percent of Americans receive a cancer diagnosis in their lifetime, amounting to over 600,000 American deaths on average every year or nearly 1,700 loved ones a day. But could hope be on the horizon thanks to technological developments like multi-cancer early detection (MCED)? Find out with Dr. Paul Doghramji and Dr. Joshua Ofman, a public health services researcher as well as the Chief Medical Officer and Head of External Affairs at GRAIL.
Guest: Edward B. Garon, MD
Could a new standard of treatment be on the horizon for patients with HER2 mutated NSCLC? Dr. Edward Garon, a Thoracic Medical Oncologist at UCLA Health, shares key takeaways on non-small cell lung cancer from the ESMO 2021 Congress.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Elizabeth A. Brem, MD
Guest: Ehab L. Atallah, MD
Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine and Dr. Ehab Atallah, a Professor of Medicine and Section Head of Hematological Malignancies in the Medical College of Wisconsin’s Division of Hematology and Oncology join Dr. Charles Turck to explore collaborative approaches and share best practices in the management of chronic lymphocytic leukemia.
Guest: James G. Christensen, MD
Catch up on how new research presented at the 2021 ESMO Congress is helping to evolve targeted therapies for colorectal and pancreatic cancer with Dr. James G. Christensen.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Jacob Sands, MD
Guest: Shirish Gadgeel, MD
Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.
Host: Jacob Sands, MD
Guest: Benjamin Kann, MD
Artificial intelligence-based models have become a growing area of interest in clinical oncology. What do we need to know about them? Dr. Benjamin Kann, a physician at Dana Farber Cancer Institute, and Assistant Professor of radiation oncology at Harvard Medical School, meets with Dr. Jacob Sands to discuss the use of AI in oncology.
Host: Jennifer Caudle, DO
Guest: Lindsey Roeker, MD
Dr. Jennifer Caudle is joined by Dr. Lindsey Roeker, a hematologist and medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss evolving outcome measures and critical diagnostic biomarkers in patients with chronic lymphocytic leukemia.
Host: Jacob Sands, MD
Guest: Bruce D. Cheson, MD, FACP, FAAAS, FASCO
Is frontline treatment for chronic lymphocytic leukemia evolving? Dr. Jacob Sands is joined by Dr. Bruce Cheson, a Scientific Advisor at the Lymphoma Research Foundation, to review the CLL treatment landscape and take a look at emerging data on long-term outcomes.
Host: Jennifer Caudle, DO
Guest: Jennifer A. Woyach, MD
Dr. Jennifer Caudle is joined by Dr. Jennifer A. Woyach, a professor in the Division of Hematology at Ohio State University, to discuss tailoring treatment to unique populations for patients with chronic lymphocytic leukemia.
Guest: Brian Hill, MD, PhD
Dr. Brian T. Hill, a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic, explores some of the most recent—and ongoing—impacts of the COVID-19 pandemic on treatment decision-making for patients with chronic lymphocytic leukemia.
Host: Jacob Sands, MD
Guest: Elizabeth A. Brem, MD
Dr. Jacob Sands is joined by Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine to explore opportunities and challenges with fixed duration therapy for patients with chronic lymphocytic leukemia.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Jacob Sands, MD
Guest: Brad McGregor, MD
Non-clear cell renal cell carcinoma is one of the rare diseases with limited treatment data, creating many challenges for oncologists. But could recent updates radically change the landscape? To find out, Dr. Jacob Sands speaks with Dr. Brad McGregor, the Clinical Director for the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, to discuss developments in the management of non-clear cell renal cell carcinoma.
Host: Jacob Sands, MD
Guest: Derek Raghavan, MD, PhD, FACP, FRACP
CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Guest: Rana McKay, MD
Host: Paul P. Doghramji, MD, FAAFP
Dr. Rana Mckay, a Medical Oncologist and Assistant Professor of Medicine at the University of California San Diego, explores the role of surveillance and frontline local therapy for patients with advanced renal cell carcinoma
Guest: Wenxin Xu, MD
Host: Paul P. Doghramji, MD, FAAFP
Dr. Paul Doghramji joins Dr. Wenxin Xu, a physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, to take a look at some of the key factors guiding treatment decisions and disease management for patients with advanced renal cell carcinoma.
Host: Matt Birnholz, MD
Guest: Jacob Sands, MD
ReachMD hosts Drs. Matt Birnholz and Jacob Sands come together to discuss the rationales, limitations, and pathways forward in the treatment of relapsing small cell lung cancer as well as platinum rechallenge therapy.
Guest: David R. Gandara, MD
Dr. David R. Gandara walks us through some of the most recent clinical trial data on non-small cell lung cancer from the 2021 American Society of Clinical Oncology Annual Meeting.
Guest: Rami Manochakian, MD
Dr. Rami Manochakian, a thoracic medical oncologist at the Mayo Clinic, dives into three clinical trials on developments in lung cancer treatment that were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Host: Jacob Sands, MD
ReachMD host Dr. Jacob Sands joins us to share key updates that were presented on lung cancer at the American Society of Clinical
Guest: Fred R. Hirsch, MD, PhD
Dr. Fred R. Hirsch, Executive Director at the Center for Thoracic Oncology in the Tisch Cancer Institute at Mount Sinai and Associate Director of Biomarker Discovery for TCI discusses key studies presented at the 2021 American Society of Clinical Oncology meeting surrounding updates in lung cancer research.
Host: Samilia Obeng-Gyasi, MD, MPH
How do surgical delays play a role in breast cancer outcomes? Dr. Samilia Obeng-Gyasi, an Assistant Professor of Surgery at Ohio State University, shares insight from her presentation at the 2021 American Society of Clinical Oncology Annual Meeting.
Guest: Maryam Lustberg, MD, MPH
In the field of breast cancer, how far have targeted therapies come? Dr. Maryam Lustberg, Assistant Professor of Internal Medicine in the Division of Medical Oncology at Ohio State University, shares some insight into the latest developments in the treatment of early-stage HER2-positive breast cancer.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lincoln Nadauld, MD, PhD
Current cancer screening methods like mammograms, colonoscopies, and CT scans are all effective in detecting cancers, but they don’t always detect cancers as early as we’d like them to, resulting in missed and delayed diagnoses. Could new technology like multicancer early detection (MCED) be the answer to addressing current unmet needs in cancer screening? Find out with Dr. Charles Turck and Dr. Lincoln Nadauld, an oncologist and the Vice President and Chief of Precision Health and Academics at Intermountain Healthcare.
Host: Jacob Sands, MD
Guest: Millie Das, MD
What are some of the latest advancements in small cell lung cancer? Dr. Jacob Sands discusses small-cell lung cancer treatment developments with Dr. Millie Das, a Clinical Associate Professor of Medical Oncology at Stanford University and Chief of Oncology at the Veteran’s Affairs Palo Alto Healthcare System.
Guest: Osita Onugha, MD, MBA
Dr. Osita Onugha, thoracic surgeon at the Providence Specialty Medical Group in Santa Monica, California, is here to share multidisciplinary strategies for the treatment of non-small cell lung cancer.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christine Bestvina, MD
Dr. Charles Turck sits down with Dr. Christine Bestvina, Assistant Professor of Medicine in the Section of Hematology and Oncology at University of Chicago Medicine, to discuss strategies to implement molecular diagnostics into clinical practice.
Guest: Osita Onugha, MD, MBA
Dr. Osita Onugha, thoracic surgeon at the Providence Specialty Medical Group in Santa Monica, California discusses how prognostic markers can be used to help guide non-small cell lung cancer treatment decisions.
Guest: Kevin Kalinsky MD, MS
In anticipation of the upcoming American Society of Clinical Oncology Annual Meeting, Dr. Kevin Kalinsky shares clinical trials and presentations that he’s looking forward to seeing.
Guest: Chandrajit P. Raut, MD, MSc
Dr. Chandrajit P. Raut, Chief of the Division of Oncology at Brigham and Women’s Hospital, gives us a sneak preview of his presentation on the surgical management of breast angiosarcoma at the upcoming 2021 American Society of Clinical Oncology Annual Meeting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nicolas Girard, MD
Dr. Charles Turck explores first-line treatment for metastatic EGFR mutated non-small cell lung cancer with pneumonologist Dr. Nicolas Girard, the head of medical oncology at the Institut Curie in Paris.
Guest: Kelly Hunt, Md
Here to give us a brief overview of her session at the 2021 American Society of Clinical Oncology Annual Meeting titled, “From Desmoid and Phyllodes to UPS: A One-Size-Does-Not-Fit-All Approach to Surgery,” is Dr. Kelly Hunt, Professor and Chair of the Department of Breast Surgical Oncology in the Division of Surgery at the University of Texas MD Anderson Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christine Bestvina, MD
Dr. Charles Turck sits down with Dr. Christine Bestvina, Assistant Professor of Medicine in the Section of Hematology and Oncology at University of Chicago Medicine, to discuss best practices and adverse events when it comes to treating non-small cell lung cancer.
Host: Jacob Sands, MD
Guest: Mark Awad, MD, PhD
Immunotherapy has led to impressive results, but when is it needed? Dr. Jacob Sands discusses the role of immunotherapy in managing lung cancer with Dr. Mark Awad, a thoracic medical oncologist, Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School.
Host: Jacob Sands, MD
Guest: Mark Awad, MD, PhD
What do we need to know about the role of biomarkers in non-small cell lung cancer? Dr. Mark Awad from the Dana-Farber Cancer Institute explains.
Host: Lola Fayanju, MD, MA, MPHS
In light of the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Lola Fayanju, an Associate Professor of Surgery and Population Health Sciences at Duke University School of Medicine, shares with us some of the updates in breast cancer care amid the COVID-19 pandemic that she’s most excited to learn more about at the conference.
Host: Oudai Hassan, MD
Here to examine the updated ASCO and CAP joint guidelines and their recommendations in the ongoing mission to improve the accuracy of HER2 testing is Dr. Oudai Hassan.
Guest: D. Ross Camidge, MD, PhD
After starting on a RET inhibitor, what do you do? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, breaks down the progression of RET inhibitors in patients with non-small cell lung cancer and what tests should be utilized throughout the process.
Guest: D. Ross Camidge, MD, PhD
With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.
Guest: Michael R. Shafique, MD
Once we identify RET fusion abnormalities in patients with non-small cell lung cancer, what targeted therapies are available to us? Tune in to hear Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center, share a brief overview of targeted therapies for patients with RET-rearranged non-small cell lung cancer.
Guest: Michael R. Shafique, MD
Here to give us a look at the unique genetic characteristics and prognostic implications for male and female patients with non-small cell lung cancer who harbor the RET fusion gene is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.
Host: Matthew J. Ellis, MD
What do we need to know about the Microscaled Proteogenomic Analysis method and the potential impacts of providing detailed tissue analyses from single-core needle biopsies? Here to talk about this new diagnostic tool for breast cancer is Dr. Matthew Ellis, Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine.
Host: Pallav Mehta, MD
What is the role of autoantibodies in breast cancer detection? Dr. Pallav Mehta, the Director of Integrative Oncology and Practice Development at the MD Anderson Cancer Center at Cooper University Health Care, shares the latest research on autoantibodies as potential biomarkers in the early detection of breast cancer?
Host: Erika Hamilton, MD
Join Dr. Erika Hamilton as she reviews the molecular subtypes of early-stage breast cancer and the shift towards personalized approaches to treatment with targeted therapies.
Host: Jacob Sands, MD
Guest: Lori Pierce, MD, FASTRO, FASCO
With only 3% of practicing oncologists identifying as Black, and less than 5% identifying as Latinx, how can we ensure these patient populations are equally represented in medical practice? Dr. Jacob Sands meets with ASCO’s current President, Dr. Lori Pierce, a Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs at the University of Michigan, to discuss ASCO’s plan to increase quality in cancer care and research.
Guest: D. Ross Camidge, MD, PhD
What are some of the clinical considerations for RET-rearranged non-small cell lung cancer? Dr. Ross Camidge, Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, briefly discusses the guidelines and benefits of therapy recommended for non-small cell lung cancer by the National Comprehensive Cancer Network.
Host: Jacob Sands, MD
Guest: Andrea B. McKee, MD
Lung cancer screening is one of the most critical components of reducing cancer mortality rates. Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, joins Dr. Jacob Sands to discuss updates in lung screening.
Host: Jacob Sands, MD
Guest: Andrea B. McKee, MD
How can a lung screening program enhance the quality of care for patients with lung cancer? Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, shares how she and her colleagues designed this program at Lahey Hospital and Medical Center.
Guest: Manisha Bahl, MD
What’s recent research saying about the use of tomosynthesis versus conventional 2D digital mammography to screen for breast cancer? Find out with Dr. Manisha Bahl, a breast imaging radiologist and Assistant Professor of Radiology at Harvard Medical Center.
Host: Jacob Sands, MD
Guest: Aaron S. Mansfield, MD
There are different treatment options available for early-stage mesothelioma, and there seem to be differences in standard practice from one center to the next. Joining Dr. Jacob Sands to share how he approaches the treatment of early-stage mesothelioma using the latest options is Dr. Aaron Mansfield, an Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.
Host: Pallav Mehta, MD
What do the updated prevention and risk screening strategies for breast cancer look like in practice? Here to share how the MD Anderson Cancer Center at Cooper University Health Care has adopted those strategies is Dr. Pallav Mehta.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Balazs Halmos, MD, MS
What are some of the most recent advancements in RET diagnostics? Dr. Balazs Halmos discusses molecular testing for patients with non-small cell lung cancer, or NSCLC, and best practices to use when treating patients with RET alterations.
Guest: Balazs Halmos, MD, MS
How is multiplex testing with next-generation sequencing different from other diagnostic tools? Dr. Balazs Halmos, the Director of Thoracic Oncology and Clinical Cancer Genomics at Montefiore Medical Park at Eastchester in the Bronx, New York, discusses how this type of testing can contribute to improved health outcomes and tailored treatment regimens for patients with non-small cell lung cancer, or NSCLC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrea B. McKee, MD
Often diagnosed in its later stages, lung cancer often leaves little time for treatment. But an preventive screening technique may help detect this disease early on. Andrea Mckee discusses the lung cancer screening guidelines from the U.S. Preventative Services Task Force and what to know about prevention screening using a low dose computed tomography (LDCT) to help close the time gap.
Guest: Pavani Chalasani MD, MPH
Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, discusses the utility of prognostic markers to improve outcomes for patients with breast cancer.
Guest: Lajos Pusztai, MD
What are the current rationales for the use of adjuvant therapies in the management of early-stage breast cancer patients? Here to share some insights is Dr. Lajos Pusztai, Director of Breast Cancer Translational Research at the Yale Cancer Center.
Guest: Randy C. Miles, MD, MPH
There’s been a sharp decrease in breast cancer diagnoses since the beginning of the COVID-19 pandemic. But that doesn’t necessarily mean there are any fewer cases out there. Here to share how the COVID-19 pandemic has impacted breast cancer screening and how we can increase access to this essential proactive measure is Dr. Randy Miles, Clinical Service Chief in the Division of Breast Imaging at the Department of Radiology at the Massachusetts General Hospital.
Host: Jacob Sands, MD
Guest: Aaron S. Mansfield, MD
Mesothelioma is a cancer with limited treatment options, so how can we manage it in the first and second-line settings and beyond? Here with Dr. Jacob Sands to walk us through the various treatment approaches to mesothelioma is Dr. Aaron Mansfield, Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.
Guest: Rachel Jimenez, MD
The NCCN Clinical Practice Guidelines in Oncology provide a wealth of information in the therapeutic management of early breast cancer. But how do those guidelines vary based on tumor biology? Here to give us a brief overview is Dr. Rachel Jimenez, Associate Program Director at the Harvard Radiation Oncology Residency Program in Boston.
Host: Jacob Sands, MD
Guest: Pasi Antero Jänne, MD, PhD
Once we’ve confirmed a patient has EGFR-mutated lung cancer, how can we treat them? Joining Dr. Jacob Sands to discuss the current and future treatments for this mutation is Dr. Pasi Janne, a translational thoracic medical oncologist at the Dana-Farber Cancer Institute.
Host: Jacob Sands, MD
Guest: Benjamin Levy, MD
What is genomic testing, and how has this advancement become such an important part of lung cancer treatment? Dr. Jacob Sands is joined Dr. Ben Levy, an associate professor of oncology at the Johns Hopkins University School of Medicine to discuss targeted therapies and testing strategies in patients with lung cancer.
Host: Jacob Sands, MD
Guest: Lawrence Nathan Shulman, MD
How do challenges in our healthcare system and disparities in access to care impact cancer patients within our communities? Dr. Jacob Sands and Dr. Lawrence Shulman continue their important conversation on oncology around the world.
Host: Jacob Sands, MD
Guest: Lawrence Nathan Shulman, MD
Oncology is a rapidly evolving field, so what do you we need to know about developments in cancer care around the world? Dr. Jacob Sands joins Dr. Lawrence Shulman, the Deputy Director of Clinical Services, Director of the Center of Global Cancer Medicine at the University of Pennsylvania, and a senior oncology advisor to Partners In Health, to give us a global perspective on cancer care.
Guest: Joseph Mikhael, MD
A 15-minute synopsis of the top hematology research in multiple myeloma presented at the 2020 ASH Annual Meeting. Learn about potential practice-changing data placed in a real-world context by a myeloma expert. This activity is an opportunity to stay up to date on the rapidly evolving myeloma landscape and to enhance your management and care strategies for patients with multiple myeloma.
Host: Jacob Sands, MD
Cancer care has evolved since the initial outbreak of the COVID-19 pandemic. What do we need to know about caring for our cancer patients during this winter season? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston shares what cancer patients can do to take care of themselves during the winter season.
Host: Jacob Sands, MD
How has cancer care changed from the initial outbreak of the COVID-19 pandemic? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston, shares how he has been treating his patients during the COVID-19 pandemic.
Guest: Mariana Chavez MacGregor, MD, MSC
The healthcare disparity crisis in the breast cancer field has prevented the benefits of therapeutic advancements from being equally distributed throughout all populations. What can we do to overcome this obstacle? Dr. Mariana Chavez MacGregor, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the disparities she's encountered in breast cancer care.
Guest: Christopher Lathan, MD, MS, MPH
Healthcare professionals have found that zip code is a better indicator of health for many patients rather than cholesterol or genetics, highlighting a significant disparity in the field of medicine. What can we do to overcome this obstacle? Dr. Christopher Lathan, Associate Medical Director of the Dana Farber Cancer Institute Network, explains how we can better connect with our patients to improve their care.
Host: Jacob Sands, MD
Guest: Christopher Lathan, MD, MS, MPH
Oftentimes, a patient’s zip code is a better indicator of health than blood pressure or genetics, highlighting a significant disparity among communities. How are barriers such as systemic racism contributing to this disparity, and what can we do to change that? Dr. Jacob Sands is joined by Dr. Christopher Lathan to discuss medical disparities as a result of systemic racism.
Host: Jacob Sands, MD
Guest: Taofeek K. Owonikoko, MD, PhD, MSCR
After years without new approvals, advancements in small cell lung cancer are at the forefront of oncology. But what do these therapeutic developments mean for the field? Dr. Taofeek Owonikoko, professor and vice-chair for faculty development in the Department of Hematology and Medical Oncology at Emory University School of Medicine, joins Dr. Jacob Sands to talk about long-awaited developments in small cell lung cancer.
Host: Jacob Sands, MD
Guest: Nabil F. Saba, MD
Since head and neck cancer is still to a large extent a surgical disease, the COVID-19 pandemic had an immediate impact on its management. Here to share how he pivoted his approach and how the pandemic might impact the future of head and neck cancer care is Dr. Nabil Saba, a Professor and Vice Chair for Quality and Safety in the Department of Hematology and Medical Oncology at the Emory University School of Medicine.
Host: Jacob Sands, MD
Guest: Nabil F. Saba, MD
Emerging research on head and neck cancer has moved away from HPV-negative diseases upon the discovery of HPV-positive diseases, specifically HPV-positive oropharynx cancer. What do we know about managing and treating this disease? Dr. Nabile Saba dives into treatment considerations, specifically immunotherapy, for patients with HPV-positive head and neck cancer.
Host: Jacob Sands, MD
Guest: Therese T. Bevers, MD
Fear of the COVID-19 pandemic has led to added safety precautions that have prevented patients from receiving much-needed cancer screenings. How will this impact the field of oncology, and what can we do to encourage patients to get their screenings? Dr. Therese Beavers, Medical Director of the Cancer Prevention Center at the University of Texas MD Anderson Cancer Center, joins Dr. Jacob Sands to discuss the fatal consequences of missed cancer screenings.
Host: John J. Russell, MD
Guest: Nabil Wasif, MD
Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.
Short for hyperthermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the benefits and drawbacks of HIPEC.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: John J. Russell, MD
Guest: Richard Wender, MD
From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations.
For more information and to review the new guidelines, go to cancer.org
Host: Brian P. McDonough, MD, FAAFP
Human papillomavirus (HPV) infection remains one of the most common sexually transmitted infections in both females and males, with about 9 in 10 people contracting HPV at some point in their lives.
Host Dr. Brian McDonough is joined by Samantha Gottlieb, medical anthropologist and author of Not Quite a Cancer Vaccine: Selling HPV and Cervical Cancer. They explore the history of Gardasil, a vaccine developed for HPV but marketed primarily as a cervical cancer vaccine, which became embroiled in sociopolitical debates about adolescent sexuality and pediatric vaccinations.
The two discuss these precedents alongside current controversies, such as whether vaccinating both males and females will induce herd immunity, and if the benefits outweigh the risks.
Host: Shira Johnson, MD
Guest: Ronald DeMatteo, MD, FACS
A Gastrointestinal Stromal Tumor (GIST) is a rare sarcoma that begins in the digestive tract or stomach, with an incident rate in the United States of approximately 4,000 to 6,000 cases per year. Since these tumors behave differently from other gastrointestinal cancers, they require a specialized treatment plan.
Host Dr. Shira Johnson chats with Ronald DeMatteo, MD, FACS, Chair of the Department of Surgery and a surgical oncologist at Penn Medicine. They discuss the diagnosis, treatment and current clinical research of GIST. Dr. DeMatteo is a world-renowned surgical expert and researcher for the rare GIST. His research breakthroughs helped develop the new standard of care for GIST.
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
Released on December 21, 2017
Host: Shira Johnson, MD
Guest: Robert Vonderheide, MD
For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer.
But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well.
Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.
Host: John J. Russell, MD
Guest: Harish Lavu, MD
Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations.
Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the diagnostic and therapeutic priorities addressing pancreatic cancer, and why this disease is so hard to detect.
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
Released July 25, 2017
Host: Brian P. McDonough, MD, FAAFP
It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care?
Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Released May 30, 2017.
Host: Jennifer Caudle, DO
Guest: Major Kenneth Lee, IV, MD, PhD
Though a relatively rare disease, pancreatic cancer remains at the forefront of clinical discussion due to its highly aggressive nature. Dr. Major Kenneth Lee, Assistant Professor of Surgery at Penn Medicine, estimates that pancreatic cancer will become the number 2 cause of cancer death by the year 2020. This projected rise in mortality is largely due to the need for better advancement in treatment options.
Join host Dr. Jennifer Caudle and guest, Dr. Major Kenneth Lee, as they discuss major signs and symptoms associated with a pancreatic cancer diagnosis, risk factors, and treatment options.
FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
Released May 22, 2017
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Released May 18, 2017
Host: Matt Birnholz, MD
Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide.
Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Medicine, about new screening guidelines for detecting colorectal cancer.
Host: Matt Birnholz, MD
Guest: Ari Brooks, MD
Guest: Brian Englander, MD
Host Dr. Matt Birnholz is joined by Dr. Ari Brooks, Director of Endocrine and Oncology Surgery and Director of the Integrated Breast Center at Pennsylvania Hospital, and Dr. Brian Englander, Clinical Assistant Professor and Chair of the Department of Radiology at Pennsylvania Hospital. Drs. Brooks and Englander discuss the hot topics within breast cancer innovations. They touch upon the increase in involvement of genetics and genomic research that is impacting breast cancer treatment options, new breast imaging modalities, and continuity of care.
Host: Matt Birnholz, MD
Guest: Taine Pechet, MD
Dr. Taine Pechet, chief of surgery at Penn Presbyterian Medical Center and associate professor of clinical surgery at Penn Medicine joins host Dr. Matt Birnholz to discuss his thoughts on who should be regularly screen for lung cancer and the various diagnostic techniques from his perspective as a thoracic surgeon. Dr. Pechet also discusses the surgical outcomes for these patient and his thoughts on what is on the horizon for the lung cancer field.
Host: Matt Birnholz, MD
Cannabis is gaining increased acceptance within the medical community for pain relief and other supportive care applications. But for oncology specialties, the use of cannabis may additionally extend into therapeutic purposes for patients.
From the floors of the A4M Conference in Las Vegas, Dr. Matt Birnholz speaks with Constance Finley, Founder and CEO of Constance Therapeutics, a California-based cannabis collective. The two discuss cannabis and cannabis oil applications for cancer patients, and their potential therapeutic effects.
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. Host Dr. Renee Allen is joined by Dr. Evelyn Reynolds to discuss critical updates in ovarian cancer, specifically dispelling the myth about ovarian cancer being a "silent killer." Dr. Reynolds an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine. She is board-certified in General Obstetrics and Gynecology and also Gynecologic Oncology.
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
What is the role and importance of the Ob-Gyn Oncologist, especially for women diagnosed with pelvic cancers? What are some barriers patients face in seeing an Ob-Gyn Oncoloogist? And how can clinicians better partner with this group of specialists? In this episode, host Dr. Renee Allen explores answers to these questions with guest expert Dr. Evelyn Reynolds, board certified physician in both General Obstetrics & Gynecology and Gynecologic Oncology. She is also an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine.
Host: Matt Birnholz, MD
Guest: Edward R. Sauter, MD, PhD, MHA
In the clinical arena, discussions on breast cancer prevention and treatment often center on what is considered most "cutting edge," from genetic mechanisms of disease to new combination pharmacotherapies to breast-conserving surgical innovations. But another field of study, targeting the potential roles of nutrition in breast cancer risk, remains commonly neglected by the medical community. What parts do nutritional choices and habits play in breast cancer development, and how can clinicians make better risk assessments given this information?
Dr. Edward Sauter, Professor of Surgery and Director of the Cancer Treatment and Prevention Center at the University of Texas Health Sciences Center, joins Dr. Matt Birnholz to discuss emerging connections between nutrition and breast cancer.